endo-BCN-PEG2-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. endo-BCN-PEG2-NHS ester contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

EN1441 is a covalent degrader targeting the androgen receptor (AR) with an EC50 value of 4.2 μM and its truncated variant AR-V7. EN1441 selectively and potently degrades both AR and AR-V7 in androgen-independent prostate cancer cells. EN1441 is promising for research of androgen-independent prostate cancers.

EB-TCIP (BAK-04-212) is a bivalent molecule comprised of AP1867 and BI-3812. EB-TCIP can form a reversible ternary complex between FKBPF36V and BCL6BTB. EB-TCIP recruits FKBP12F36V-tagged EWS/FLI1 to DNA sites bound by the transcriptional regulator BCL6, leading to rapid expression of BCL6 target genes (eg: SOCS2 and CXCL11). EWS/FLI1 is a fusion transcription factors in Ewing sarcoma. EB-TCIP can be used for research of deregulated transcription in cancer.

E197 is the inhibitor for DOCK5 that destroys the podosome belt structure of osteoclasts, thereby inhibiting the bone resorption (IC50=3.44 μM in human osteoclast). E197 inhibits the Rac in DOCK5 expressing HEK293 cell with an IC50 of 36 μM. E197 prevents the bone loss in mouse ovariectomized models.

DS-1150b is an orally active GLUT4 activator. DS-1150b has the activity of activating GLUT4 transport and can promote the translocation of GLUT4 to the cell membrane in skeletal muscle cells. DS-1150b has shown hypoglycemic effects in the Zucker obese rat model and can be used in the study of type 2 diabetes mellitus (T2DM).

DPM-1003 is a PTP1B conformational inhibitor that targets the non-catalytic, disordered segment at the C-terminus of the PTP1B protein, showing improvement in lung inflammation in mice.

DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact.

DOTAGA-FAP-2286-ALB is a derivative of Rofapitide tetraxetan. m3227G(

Donepezil N-oxide, a metabolite of Donepezil. Ogerin analogue 1 is generally used as a negative control.

Docosapentaenoic acid (22n-3) sodium is a component of phospholipids. Docosapentaenoic acid 22n-3 sodium has inhibitory activity against α-amylase and α-glucosidase, with IC50s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 sodium increases cell vitality. Docosapentaenoic acid 22n-3 sodium has a weak anti-inflammatory effect.

DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL). DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research.

DM21-L-G is a Drug-Linker Conjugates that can be used to synthesize ADC molecules.

DL5055 (compound 6k) is a potent and selective hCAR activator with an EC50 of 0.35 μM. DL5055 induces CYP2B6 expression and hCAR nuclear translocation in human primary hepatocytes.

DL-01 TFA is the TFA salt form of DL-01. GSK-364735 potassium is an antiretroviral, that inhibits the integrase of human immunodeficiency virus type 1 (HIV-

Dihydroxyacetone phosphate dilithium (DHAP) is used for studies of fructose metabolism, trioses and glycosylation. Dihydroxyacetone phosphate dilithium is used for studies involving the metabolism of trisaccharide pools and their roles in physiological and physical processes.

Diclofenac amide is a prodrug for Diclofenac sodium. Diclofenac amide is an orally active inhibitor for COX-1/2, that inhibits the production of prostaglandins (PG) and thromboxanes (TX). Diclofenac amide exhibits anti-inflammatory efficacy in Carrageenan-induced rat paw edema model without causing gastric ulcer (300 μmol/kg).

Desthiazolylmethyl ritonavir is a base-catalyzed degradation product of the HIV protease inhibitor Ritonavir, black: linker, Blue: E3 ligase ligand).

DEL-I25 is a potent GPX4 activator. DEL-I25 protects cells from ferroptosis.

DEG-35 is a CRBN-dependent, dual IKZF2 and CK1α molecule glue degrader, with DC50 values of 1.4 nM and 4.4 nM for CK1α and IKZF2, respectively. DEG-35 activates the p53 apoptosis pathway. DEG-35 can be used in the research for Acute Myeloid Leukemia (AML).

Defactinib analogue-1 (Compound 7) is a ligand for target protein Fak, that can be used for synthesis of PROTAC FAK degrader 1. 11(Z),14(Z)-Eicosadienoic acid ethanolamide inhibits the inactivating transport of an endogenous cannabinoid substance with an IC50 value of 10.6 μM. 11(Z),14(Z)-Eicosadienoic acid ethanolamide can be used for research of neuropsychiatric conditions.

DDO-6691 is a heat shock protein 90 (HSP90) inhibitor. DDO-6691 has antiproliferative effects on a variety of tumor cells, with HCT-116 colon cancer cells being the most sensitive (IC50: 1.08 μM). DDO-6691 exhibits potent tumor growth inhibition in the HCT-116 xenograft mouse model.

DDO-6079 is a potent CDC37 inhibitor. DDO-6079 inhibits HSP90-CDC37 and CDC37-CDK4/6 chaperone complex by binding to an allosteric site on CDC37. DDO-6079 decreases the thermostability of CDK6.

DDL-357 is a potent secreted clusterin enhancer. DDL-357 reduces phospho-tau in brain and improves memory in the murine 3xTg-AD model.

DDHF20 is an antimicrobial agent against Staphylococcus aureus, targeting and inhibiting its thioredoxin reductase (TrxR). It acts as a competitive inhibitor for the NADPH binding site. DDHF20 is expected to be used in research related to antimicrobial infections caused by Staphylococcus aureus.

DCG04 isomer-1 is an isomer of DCG04.

DC20 is an orally active non-nucleoside reverse transcriptase inhibitor with an EC50 of 0.004 μM aganist HIV-1IIIB.

DBL-6-13 is an inhibitor for WDR5 with a moderate binding affinity of 6.8 μM (microscale thermophoresis assay) and 9.1 μM (fluorescence polarization assay).

DBCO-PEG3-NHS is a biochemical assay reagent, that can be used to chemically modify proteins and antibodies with an alkynyl (DBCO) or N-hydroxysuccinimide (NHS) ester group. DBCO-PEG3-NHS can be used as a linker in PROTAC synthesis or for drug delivery and the development of biosensors and diagnostic reagents.

DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.

Darlifarnib (Compound (S)-058) is the inhibitor for farnesyl transferase and geranylgeranyltransferase with IC50 ≤ 10 nM and ＞ 1000 nM. Darlifarnib exhibits good metabolic stability in human and mouse liver microsomes with the half-life time ＞ 100 min.